Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05926050 · ClinicalTrials.gov registry record · NA
The Acute Effects of a Dietary Supplement on Cognitive Performance in Highly Trained Athletes.
A NA study of Reaction Time, sponsored by USANA Health Sciences.
- Completed
- Registry status
- NA
- Development phase
- 41
- Enrollment target
- 1
- Study location
NCT05926050: Completed NA study of Reaction Time, sponsored by USANA Health Sciences.
NCT05926050 is a NA study of Reaction Time that has completed, run by USANA Health Sciences. The registered enrollment target is 41 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05926050, a NA study of Reaction Time, has completed, sponsored by USANA Health Sciences.
- COMPLETED
- Registry status
- NA
- Development phase
- 41 participants
- Enrollment target
- 1
- Study location
Study Summary
This study was designed to determine if a dietary supplement containing extracts of American ginseng, bacopa monnieri and coffee fruit can enhance cognitive performance in a population of trained athletes.
Primary Outcome
Participants will perform a series of reaction time tasks prior to and after consumption of either the treatment or placebo tablets. Reaction times will be quantified and analyzed to determine if the intervention affected these measures.
Conditions Studied
Interventions
- OTHER Placebo
- DIETARY_SUPPLEMENT Treatment (CopaPrime+ (USANA Health Sciences)
Study Locations (1)
Utah
- US Ski and Snowboard Center of Excellence - Park City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2021-09-08 |
| Est. Completion | 2022-08-10 |
| Phase | NA |
What the finished NCT05926050 record still lists
NCT05926050 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Reaction Time appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05926050 reports a single indexed study location in Utah.
Frequently Asked Questions
What is clinical trial NCT05926050 about?
NCT05926050 is a clinical study titled "The Acute Effects of a Dietary Supplement on Cognitive Performance in Highly Trained Athletes.". This study was designed to determine if a dietary supplement containing extracts of American ginseng, bacopa monnieri and coffee fruit can enhance cognitive performance in a population of trained athletes.
What is the current status of trial NCT05926050?
This trial is currently completed. It is a NA study. The enrollment target is 41 participants. The study started on 2021-09-08. Estimated completion is 2022-08-10.
What conditions does trial NCT05926050 study?
This clinical trial studies the following conditions: Reaction Time.
What interventions are being tested in trial NCT05926050?
The interventions under investigation include: Placebo (OTHER), Treatment (CopaPrime+ (USANA Health Sciences) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05926050?
This trial is sponsored by USANA Health Sciences, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05926050 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05926050's enrollment target sits among peer trials
41 1446th of 2000 higher than 554 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI